Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL), focusing on the company's progress with IHL-42X for obstructive sleep apnea (OSA). The update follows the full Phase 2 RePOSA data and exit-interview analyses, which demonstrated statistically significant reductions in Apnea-Hypopnoea Index (AHI) for both low and high-dose IHL-42X compared to placebo. Notably, the high-dose arm achieved maximum AHI reductions of up to 83%.
Exit interviews revealed that 57.6% of participants reported perceived improvement in their OSA, with most describing the change as meaningful to daily life. IHL-42X was well tolerated across both dose cohorts, reinforcing its potential for broad use. The U.S. Food and Drug Administration has granted Fast Track designation for IHL-42X, which may expedite its development and review.
Incannex also reported $68.9 million in cash and cash equivalents, providing a strong financial foundation to advance its clinical programs. Additionally, positive Phase 2 results for PSX-001, another candidate in the pipeline, were noted.
Stonegate Capital Partners is a capital markets advisory firm offering investor relations, equity research, and institutional investor outreach services. Its affiliate, Stonegate Capital Markets (member FINRA), provides investment banking services for public and private companies.
For more details, the full announcement is available at https://www.stonegateinc.com.
